VIR News and Press, Vir Biotechnology Inc. From 06/25/22

– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the ...

The pharmaceutical/biotechnology subsector has the best value and quality scores. Healthcare equipment is the most overvalued industry. IHF: a concentrated ETF in healthcare providers. 10 stocks cheaper than their peers in June. For further details see: IHF: Healthca...

With the S&P 500 down over 23% year to date, investors looking for safety are eyeing the healthcare industry. Indeed, the S&P 500 Healthcare index is down just under 15% since the start of the year, outpacing the broader markets. People will need healthcare regardless of the eco...

The odds of developing long COVID were between 20-50% lower during the Omicron wave of the pandemic than the Delta period according to the first of its kind study published in a peer-reviewed journal. The results varied depending on age and time since vaccination. Long COVID is characterized ...

SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ ...

Shares of Xencor have fallen by 46% since my 2019 update. I initially liked this one for "picks and shovels" aspect of the story. XmAb technology is being utilized by a variety of big pharmaceutical companies, with focus on bispecific antibodies and engineered cytokines. Xencor is...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bill Gates reportedly has a half a billion dollar short on TSLA stock The short was revealed through a text message conversation with Elon Musk Gates’ largest holding is Berkshire Hathaway Class B (NYSE: ...

One in five COVID-19 survivors aged 18 – 64 years in the U.S. may have developed at least one condition linked to long COVID, a large new study conducted by the Centers for Disease Control and Prevention (CDC) indicates. The prevalence is even higher among those aged 65 years and older...

As the demand dries up and the pandemic evolves, Wall Street projects the sales for COVID-19 vaccines and therapeutics to plateau amid ample supplies while companies continue to assess the outlook. “This year is probably the peak, then going forward, it’s going to decline,ȁ...

Vir Biotechnology (NASDAQ:VIR) announced on Friday that its Chinese partner WuXi Biologics (OTCPK:WXXWY) (OTCPK:WXIBF) ended its partnership for development and manufacturing for several of company’s antibody drugs including the COVID-19 antibody therapy sotrovimab. Per the terms of th...